Importantly, the addition of pembrolizumab did not result in a marked increase in severe toxicity, making it a viable frontline treatment option for metastatic NSCLC patients with PD-L1 expression ≥1% [72,73]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.